Posts by: Forest Ray

Forest Ray

Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.

November 12, 2020November 12, 2020

Breast Cancer Cell Sugars in Liquid Biopsies Could Be Key to Early Detection

News

The sugars that breast cancer cells shed into the bloodstream could provide an early cancer warning, according to a press release from GlycoNet, Canada’s national network of sugar science ... Read more

November 5, 2020November 5, 2020

Phase 3 Trial to Compare Enhertu to Kadcyla in HER2-Positive, High Risk Patients

News

Daiichi Sankyo and AstraZeneca are initiating a global Phase 3 trial to compare Enhertu (fam-trastuzumab deruxtecan-nxki) to Kadcyla (ado-trastuzumab emtansine, also called T-DM1) as adjuvant therapy in patients with HER2-positive early ... Read more

October 8, 2020October 8, 2020

FDA Puts Eganelisib on Fast Track for Advanced Triple-negative Breast Cancer

News

The U.S. Food and Drug Administration has granted fast track status to immuno-oncology candidate eganelisib (IPI-549) in combination with a checkpoint inhibitor and chemotherapy as a first-line treatment for patients ... Read more

September 10, 2020September 10, 2020

Tesetaxel With Reduced-dose Capecitabine Improved Progression-free Survival in Metastatic Breast Cancer

News

Odonate Therapeutics announced that tesetaxel, together with a reduced dose of capecitabine, improved progression-free survival in metastatic breast cancer patients taking part in a Phase 3 clinical trial. Median progression-free ... Read more

August 31, 2020August 31, 2020

Phase 2 Trial Launched to Test CFI-400945 Plus Imfinzi in Advanced TNBC

News

The Canadian Cancer Trials Group (CCTG) has launched a Phase 2 study of CFI-400945 in combination with Imfinzi (durvalumab) for the treatment of advanced or metastatic triple negative breast cancer ... Read more

July 9, 2020July 9, 2020

EMA Grants Trastuzumab Deruxtecan Accelerated Assessment for Advanced HER2-positive Breast Cancer

News

The European Medicines Agency (EMA) has validated Daiichi Sanyoko‘s marketing authorization application for trastuzumab deruxtecan (DS-8201) for the treatment of inoperable or metastatic HER2-positive breast cancer, the company announced. ... Read more

June 30, 2020June 30, 2020

FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

News, syndicated

The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a publicly available information bank describing patient-reported symptoms from cancer trials for ... Read more

June 29, 2020June 29, 2020

Cancer Vaccine Combo to be Tested in Triple Negative Breast Cancer

News

UbiVac and Bristol Myers Squibb have announced plans to collaborate on a clinical trial to test whether a combination therapy approach can boost cancer immunity in patients with advanced ... Read more